Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Cytomegalovirus in hematopoietic stem cell transplant recipients.

Hematology/oncology clinics of North America

Ljungman P, Hakki M, Boeckh M.
PMID: 21236396
Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011.

This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined.

Cite
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151-69doi: 10.1016/j.hoc.2010.11.011.
Ljungman, P., Hakki, M., & Boeckh, M. (2011). Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematology/oncology clinics of North America, 25(1), 151-69. https://doi.org/10.1016/j.hoc.2010.11.011
Ljungman, Per, et al. "Cytomegalovirus in hematopoietic stem cell transplant recipients." Hematology/oncology clinics of North America vol. 25,1 (2011): 151-69. doi: https://doi.org/10.1016/j.hoc.2010.11.011
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011. PMID: 21236396; PMCID: PMC3340426.
Copy Download .nbib Format: NLM
Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation.

Blood

Casto AM, Seo S, Levine DM, Storer BE, Dong X, Hansen JA, Boeckh M, Martin PJ.
PMID: 34269803
Blood. 2021 Oct 28;138(17):1628-1636. doi: 10.1182/blood.2021012153.

Human cytomegalovirus (CMV) reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Despite routine screening for CMV reactivation and early antiviral treatment, the rates of CMV-related complications after HCT remain high. Genetic variants in both the donor...

Cite
Casto AM, Seo S, Levine DM, et al. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood. 2021;138(17):1628-1636doi: 10.1182/blood.2021012153.
Casto, A. M., Seo, S., Levine, D. M., Storer, B. E., Dong, X., Hansen, J. A., Boeckh, M., & Martin, P. J. (2021). Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood, 138(17), 1628-1636. https://doi.org/10.1182/blood.2021012153
Casto, Amanda M, et al. "Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation." Blood vol. 138,17 (2021): 1628-1636. doi: https://doi.org/10.1182/blood.2021012153
Casto AM, Seo S, Levine DM, Storer BE, Dong X, Hansen JA, Boeckh M, Martin PJ. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood. 2021 Oct 28;138(17):1628-1636. doi: 10.1182/blood.2021012153. PMID: 34269803; PMCID: PMC8554648.
Copy Download .nbib Format: NLM
Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies.

The Journal of infectious diseases

Imlay H, Dasgupta S, Boeckh M, Stapleton RD, Rubenfeld GD, Chen Y, Limaye AP.
PMID: 33159200
J Infect Dis. 2021 Jun 15;223(12):2108-2112. doi: 10.1093/infdis/jiaa697.

We performed multivariable analysis of potential risk factors (including cytomegalovirus [CMV] reactivation) for clinical outcomes by day 28 (death or continued hospitalization, ventilator-free days, intensive care unit (ICU)-free days, hospital-free days) from pooled cohorts of 2 previous prospective studies...

Cite
Imlay H, Dasgupta S, Boeckh M, et al. Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. J Infect Dis. 2021;223(12):2108-2112doi: 10.1093/infdis/jiaa697.
Imlay, H., Dasgupta, S., Boeckh, M., Stapleton, R. D., Rubenfeld, G. D., Chen, Y., & Limaye, A. P. (2021). Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. The Journal of infectious diseases, 223(12), 2108-2112. https://doi.org/10.1093/infdis/jiaa697
Imlay, Hannah, et al. "Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies." The Journal of infectious diseases vol. 223,12 (2021): 2108-2112. doi: https://doi.org/10.1093/infdis/jiaa697
Imlay H, Dasgupta S, Boeckh M, Stapleton RD, Rubenfeld GD, Chen Y, Limaye AP. Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. J Infect Dis. 2021 Jun 15;223(12):2108-2112. doi: 10.1093/infdis/jiaa697. PMID: 33159200; PMCID: PMC8496661.
Copy Download .nbib Format: NLM
A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL.

Contemporary clinical trials communications

Kimball LE, Stevens-Ayers T, Green ML, Xie H, Flowers ME, Jerome KR, LeBlanc R, Dahlgren C, Nichols WG, Chemaly RF, Papanicolaou G, Boeckh M.
PMID: 28184381
Contemp Clin Trials Commun. 2016 Dec 15;4:84-89. doi: 10.1016/j.conctc.2016.05.002. Epub 2016 May 05.

PURPOSE: The logistics of conducting double-blinded phase III clinical trials with participants residing in remote locations are complex. Here we describe the implementation of an interventional trial for the prevention of late cytomegalovirus (CMV) disease in hematopoietic cell transplantation...

Cite
Kimball LE, Stevens-Ayers T, Green ML, et al. A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL. Contemp Clin Trials Commun. 2016;4:84-89doi: 10.1016/j.conctc.2016.05.002.
Kimball, L. E., Stevens-Ayers, T., Green, M. L., Xie, H., Flowers, M. E., Jerome, K. R., LeBlanc, R., Dahlgren, C., Nichols, W. G., Chemaly, R. F., Papanicolaou, G., & Boeckh, M. (2016). A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL. Contemporary clinical trials communications, 484-89. https://doi.org/10.1016/j.conctc.2016.05.002
Kimball, Louise E, et al. "A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL." Contemporary clinical trials communications vol. 4 (2016): 84-89. doi: https://doi.org/10.1016/j.conctc.2016.05.002
Kimball LE, Stevens-Ayers T, Green ML, Xie H, Flowers ME, Jerome KR, LeBlanc R, Dahlgren C, Nichols WG, Chemaly RF, Papanicolaou G, Boeckh M. A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL. Contemp Clin Trials Commun. 2016 Dec 15;4:84-89. doi: 10.1016/j.conctc.2016.05.002. Epub 2016 May 05. PMID: 28184381; PMCID: PMC5292623.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries